|View printer-friendly version|
|June 28, 2005 11:30 a.m.|
|Teva And Active Biotech Announce The Submission Of An Ind To The Fda For Laquinimod, An Oral Product For The Treatment Of Relapsing Ms|
Jerusalem, Israel, June 28, 2005 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech AB (Stockholm: ACTI.ST) announced today the submission of an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) to initiate a clinical trial in the U.S. with laquinimod to assess drug-drug interaction. Based on the results of this study and of the ongoing phase IIb study in Europe (see below), the phase III clinical program to confirm the efficacy and safety of laquinimod in relapsing forms of MS, is planned to start in 2006.